Last Price
17.59
Today's Change
+0.02 (0.11%)
Day's Change
17.18 - 18.02
Trading Volume
565,196
Market Cap
1 Billion
Shares Outstanding
75 Million
Avg Volume
793,383
Avg Price (50 Days)
19.56
Avg Price (200 Days)
20.83
PE Ratio
-6.11
EPS
-2.88
Earnings Announcement
08-Apr-2025
Previous Close
17.57
Open
17.67
Day's Range
17.18 - 18.02
Year Range
9.52 - 29.56
Trading Volume
544,432
1 Day Change
0.11%
5 Day Change
-9.10%
1 Month Change
-9.75%
3 Month Change
-23.25%
6 Month Change
-21.05%
Ytd Change
-9.84%
1 Year Change
78.22%
3 Year Change
9.25%
5 Year Change
-7.47%
10 Year Change
-7.47%
Max Change
-7.47%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.